Regina Kunz, MD, MSc(Epi); Chris Friedrich, MD; Marcel Wolbers, PhD; Johannes F.E. Mann, MD
Acknowledgment: The authors thank Gordon Guyatt for constructive discussions and Jan Friedrich for sharing details regarding the methods of generating ratios of means.
Potential Financial Conflicts of Interest:Honoraria: J.F.E. Mann (Boehringer-Ingelheim, Novartis, Aventis). Grants received: J.F.E. Mann (Aventis, Novartis).
Reproducible Research Statement: For information on the protocol, statistical code, and data, contact Dr. Regina Kunz at email@example.com.
Requests for Single Reprints: Regina Kunz, MD, MSc, Basel Institute for Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, 4031 Basel, Switzerland; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Kunz and Wolbers: Basel Institute for Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, 4031 Basel, Switzerland.
Drs. Friedrich and Mann: Munich General Hospital, Ludwig Maxmilian University, Kölner Platz 1, 80804 Munich, Germany
Reduction of proteinuria is associated with delayed progression of chronic kidney disease. Reports suggest that angiotensin-receptor blockers (ARBs) reduce proteinuria, but results are variable. The relative effect of ARBs and angiotensin-converting enzyme (ACE) inhibitors, and their combined administration, remains uncertain.
To establish the effect of ARBs versus placebo and alternative treatments, and the effect of combined treatment with ARBs and ACE inhibitors, on proteinuria.
English-language studies in MEDLINE and the Cochrane Library Central Register of Controlled Trials (January 1990 to September 2006), reference lists, and expert contacts.
Randomized trials of ARBs versus placebo, ACE inhibitors, calcium-channel blockers, or the combination of ARBs and ACE inhibitors in patients with or without diabetes and with microalbuminuria or proteinuria for whom data were available on urinary protein excretion at baseline and at 1 to 12 months.
Two investigators independently searched and abstracted studies.
Forty-nine studies involving 6181 participants reported results of 72 comparisons with 1 to 4 months of follow-up and 38 comparisons with 5 to 12 months of follow-up. The ARBs reduced proteinuria compared with placebo or calcium-channel blockers over 1 to 4 months (ratio of means, 0.57 [95% CI, 0.47 to 0.68] and 0.69 [CI, 0.62 to 0.77], respectively) and 5 to 12 months (ratio of means, 0.66 [CI, 0.63 to 0.69] and 0.62 [CI, 0.55 to 0.70], respectively). The ARBs and ACE inhibitors reduced proteinuria to a similar degree. The combination of ARBs and ACE inhibitors further reduced proteinuria more than either agent alone: The ratio of means for combination therapy versus ARBs was 0.76 (CI, 0.68 to 0.85) over 1 to 4 months and 0.75 (CI, 0.61 to 0.92) over 5 to 12 months; for combination therapy versus ACE inhibitors, the ratio of means was 0.78 (CI, 0.72 to 0.84) over 1 to 4 months and 0.82 (CI, 0.67 to 1.01) over 5 to 12 months. The antiproteinuric effect was consistent across subgroups.
Most studies were small, varied in quality, and did not provide reliable data on adverse drug reactions. Proteinuria reduction is only a surrogate for important progression of renal failure.
The ARBs reduce proteinuria, independent of the degree of proteinuria and of underlying disease. The magnitude of effect is similar regardless of whether the comparator is placebo or calcium-channel blocker. Reduction in proteinuria from ARBs and ACE inhibitors is similar, but their combination is more effective than either drug alone. Uncertainty concerning adverse effects and outcomes that are important to patients limits applicability of findings to clinical practice.
Although evidence suggests that both angiotensin-receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria, the relative effects of ARBs compared with ACE inhibitors and whether the effect of these agents is greater when they are used in combination are unclear.
This meta-analysis of 49 randomized trials showed that ARBs delay progression of proteinuria over the short (1 to 4 months) and longer (5 to 12 months) terms and that ARBs reduce proteinuria to a similar degree as ACE inhibitors. Although data were limited, the combination of the 2 drugs seems to reduce proteinuria more than either drug alone.
Data on adverse effects and long-term outcomes are limited.
Study flow diagram.
Table 1. Angiotensin-Receptor Blockers versus Placebo: Included Studies and Outcomes*
Table 2. Angiotensin-Receptor Blockers versus Calcium-Channel Blockers: Included Studies and Outcomes*
Table 3. Angiotensin-Receptor Blockers versus Angiotensin-Converting Enzyme Inhibitors: Included Studies and Outcomes*
Table 4. Combination Therapy versus Angiotensin-Receptor Blockers: Included Studies and Outcomes*
Table 5. Combination Therapy versus Angiotensin-Converting Enzyme Inhibitor: Included Studies and Outcomes*
Appendix Table. Methodological Quality of the Included Studies*
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; CCB = calcium-channel blocker; Combi = combination therapy.
Reduction in proteinuria at 1 to 4 months.
ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker.
Reduction in proteinuria at 5 to 12 months.
Table 6. Risk for Medication Discontinuation*
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med. ;148:30–48. doi: 10.7326/0003-4819-148-1-200801010-00190
Download citation file:
Published: Ann Intern Med. 2008;148(1):30-48.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Urological Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use